ET IN THE NEWS
​DSF is proud to announce our partnership/sponsorship with Sage Therapeutics who ​will help DSF change the future for everyone who will inherit or develop Essential Tremor by offering hope and assistance for people suffering from hardships magnified by Essential Tremor.
DSF ET Talks with Chef Virginia Willis, Diann Shaddox, & Dr. Darlene Lobel
​ET Talks Chef Virginia Willis    Staying Motivated
February is all about #LoveYourself with a whole month of doable, real-life tips on living your best life! ​
Chef Virginia Willis is a James Beard award-winning cookbook author, television personality, content creator, motivational speaker, and social media influencer. 
​Press Release; DSF President Darlene A. Lobel MD, FAANS, January 25, 2023
Diann Shaddox Foundation for Essential Tremor is proud to announce the appointment of Dr. Darlene A. Lobel as President of DSF January 25, 2023. We are excited to have Dr. Lobel to help us ensure our mission to advance knowledge and recognition of Essential Tremor to the world and find new treatments and a cure. Our end goal is to ease the suffering of Essential Tremor.
Message from DSF Executive Director
Thank you for supporting the Diann Shaddox Foundation for Essential Tremor in 2022. I am excited about our plans for 2023 and we are gearing up for a remarkable year for ET.
​
​World Movement Disorders Day 
Join Diann Shaddox, Dr. Darlene Mayo,  Dr. Drew Christensen, & Dr. Brady Dorn bringing the ET Worldwide Community together to educate and boost #movedisorder awareness on Tuesday, November 29, 2022.
ET Talks with Jazz Pharmaceuticals
​Jazz Pharmaceuticals co-hosts ET Talks, learn more about their Essential Tremor clinical Trail and what's going on with ET.
October 8, 2022 
​Time to raise awareness about essential tremor, a debilitating disorder that’s too often ignored
​The Diann Shaddox Foundation for Essential Tremor is proud to announce the appointment of Dr. Darlene A. Lobel as a new member of DSF Board of Trustees. 
Genetics of Essential TremorDate: March 2022 
Prepared by SIC member: Katja Lohmann, PhD. 
Authors: Pau Pastor, MD, PhD; Günther Deuschl, MD, PhD; Cornelis Blauwendraat, PhD.
Editor: Lorraine Kalia, MD, PhD.
Differentiation of Parkinson’s disease tremor and essential tremor based on a novel hand posture
Dr. Brady R Dorn, DC
The Diann Shaddox Foundation for Essential Tremor is proud to announce the appointment of Dr. Brady R. Dorn, DC from Oconomowoc Wisconsin as a new member of DSF Medical Advisory Board.
 
Essential Tremor: Five New Things 
​Purpose of the review: To highlight five new things in the research and clinical aspects of essential tremor (ET).
Please urge your members of Congress to fund the BRAIN Initiative and add Essential Tremor to the email. https://aan.quorum.us/campaign/39971/​
By American Academy of Neurology
​Treatment Patterns in Essential Tremor: A Retrospective Analysis
by Tremor and Other Hyperkinetic Movements https://tremorjournal.org/articles/10.5334/tohm.682/  
Rationale and Evidence for Peripheral Nerve Stimulation for Treating Essential Tremor
​The Diann Shaddox Foundation for Essential Tremor is proud to announce the appointment of Bill Hazel as a new DSF Board Trustee.
Bill is a Director at Cedar Wealth Management where the firm focuses helping clients with a variety of Investment advice ranging from retirement funds to Private Investing opportunities. Prior to joining Cedar Wealth Bill was a senior vice president and principal at Eubel Brady & Suttman Asset Management in Dayton, Ohio. Bill’s experience includes managing asset allocation, equity, and alternative strategies for institutional investors including state and local municipalities, retirement and pension funds, educational foundations, endowments and large retail organization. 
Sage & Biogen ET Clinical Trial
​About the KINETIC 2 TRIAL. Sage & Biogen are looking for adults ages 18 to 80 years old who have been formally diagnosed with essential tremor for at least three years to take part in the KINETIC 2 TRIAL. The purpose of this study is to evaluate the safety and efficacy of three different doses of an investigational drug compared to a placebo on tremor reduction. A placebo is an inactive pill that looks like the investigational drug but contains no active medication. Participation in the KINETIC 2 TRIAL lasts approximately 19 weeks, including 11 clinic visits and five phone calls from the study team.
 
Interested individuals will be evaluated to determine their eligibility to participate in this study. Each patient who participates will receive either the investigational drug or a placebo, as well as study-related medical exams and study-related laboratory tests, at no cost. To learn more, visit KINETIC2TrialET.com.
Jazz Pharmaceuticals ET Clinical Trial 
 Would you like to participate in a study for Essential Tremor (ET)?
We are inviting you to take part in a study for adults who experience tremors in an upper limb (such as your arms) due to ET. All study-related visits, tests, and investigational medication will be provided at no cost to you. In addition, reimbursement for time and travel may be provided. No health insurance is required.                                                                         Jazz Pharmaceuticals Phase 2b Clinical Trial in essential tremor. 
Physiology of Tremor Reduction by Putting the Hands Together in Essential Tremor
Praxis Precision Medicines ET Clinical Trials
PRAXIS PRECISION MEDICINES PROVIDES CORPORATE UPDATE     May 9, 2022 at 4:01 PM EDT
PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study
“This is an incredibly exciting time at Praxis, with recent events bringing us closer to our long-term vision,” said Marcio Souza, president and chief executive officer of Praxis. “With positive topline results from our PRAX-944 Phase 2a study in essential tremor, and plans to accelerate development in the ongoing Essential1 study, we will soon have a second late-stage clinical asset along with a deep and innovative early-stage pipeline. https://www.linkedin.com/company/praxis-precision-medicines-inc/videos/
Sage is proud to be named one of America’s Most Trusted Companies by Newsweek. We’re committed to shaping the future of #brainhealth and developing medicines that positively impact the lives of our patients. 
 #ThisIsSage
DSF is proud to announce our continuing partnership with Kroger Company who ​will help DSF change the future for everyone who will inherit or develop Essential Tremor by offering hope and assistance for people suffering from hardships magnified by Essential Tremor.
DSF is proud to announce our partnership/sponsorship with  Jazz Pharmaceuticals  ​who ​will help DSF change the future for everyone who will inherit or develop Essential Tremor by offering hope and assistance for people suffering from hardships magnified by Essential Tremor.
Picture
 Barry Greene CEO at Sage Therapeutics 
I welcome every opportunity to shine a light on the #brainhealth pandemic and the urgent need for innovation in care. I was thrilled to join #TEDxBoston to discuss how we are working to develop novel therapies to move from brain health awareness to brain health action. Watch my full talk here. 
​​​New Treatment Research in the News 2022
Neuroscience News
​New MRI Probe Can Reveal More of the Brain’s Inner Workings
JAMA Neurology | Original Investigation
Association of Essential Tremor With Novel Risk Loci
A Genome-Wide Association Study and Meta-analysis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for patients affected by central nervous system (“CNS”) disorders characterized by neuronal imbalance. 
Praxis  is in the process of developing a new medication specifically focused on treating Essential Tremor.
Diann Shaddox Foundation For Essential Tremor is Platinum Transparency

DSF ET talks

Cher Burnham Matteson Board Trustee & Director of Family Assistance on Facebook Live ET Talk event
​ January 8, 2022.
Talking about living with Essential Tremor
Ask Your Legislator to Support an FDA Neuroscience Center of Excellence
Congress needs to hear from you now. Please urge your member of Congress to support the creation of a Neuroscience Center of Excellence by co-sponsoring the BRAIN Act and signing the letter in support of the creation of a Neuroscience Center of Excellence today. ​
​Leaders of the Congressional Neuroscience Caucus and the Brain Injury Task Force are circulating a sign-on letter to the Energy & Commerce Committee in support of the creation of a Neuroscience Center of Excellence (NCOE) at the Food and Drug Administration (FDA). A Neuroscience Center of Excellence would help the more than ten million people living with essential tremor by creating a more transparent and patient-focused process at the FDA to speed the delivery of safe and effective treatments to patients.

Participate in Clinical Trials and Studies

millions of faces of et
​ SIGN UP FOR OUR NEWSLETTER AND GET THE LATEST INFO ON  EVENTS, FUNDRAISERS AND WAYS TO MAKE AN IMPACT.
 SIGN UP FOR OUR NEWSLETTER AND GET THE LATEST INFO ON  EVENTS, FUNDRAISERS AND WAYS TO MAKE AN IMPACT.
​
 |​DSF |  Events | Programs | Contact Us | Terms of Use  |  Privacy Policy |​  Ways to Give|​ ET |​ Treatment |​ ​
 Diann Shaddox Foundation for Essential Tremors

© 2o23 | Diann Shaddox foundation ™| All Rights Reserved.  No part of this website is public domain.  
​All contributions are tax deductible to the extent allowable by law.

Diann Shaddox Foundation for Essential Tremor A Non-Profit 501c(3) organization www.diannshaddoxfoundation.org